Search for: "Sanofi"
Results 121 - 140
of 1,187
Sorted by Relevance
|
Sort by Date
26 Aug 2019, 4:15 am
Pfizer saw a lot of success last week in having seven IPRs instituted against Sanofi-Aventis, challenging four injectable insulin treatment patents that are at the center of district court infringement litigation between the two parties. [read post]
12 Mar 2024, 9:13 pm
Sanofi Pasteur Inc., affirming the Patent Trial and Appeal Board's (PTAB) determination that all claims of U.S. [read post]
10 Oct 2011, 7:24 am
Sanofi México Av. [read post]
15 Aug 2006, 6:45 am
This is the court hearing the patent infringement suit, Sanofi-Synthelabo v. [read post]
23 Jan 2012, 4:56 pm
According to the criminal complaint, Sanofi became aware in May 2011 that, on Abby Pharmatech’s website, Abby Pharmatech was advertising chemical compounds that belonged to Sanofi, including a number which Sanofi had not yet publically disclosed. [read post]
13 Jan 2022, 3:15 am
In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. [read post]
13 Jan 2022, 3:15 am
Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate... [read post]
30 Aug 2010, 3:00 am
As we reported on August 3, Weil Gotshal is representing French drug make Sanofi in its bid for the Cambridge, Massachusetts-based biopharmaceutical company--Sanofi revealed an $18.5 billion offer on Sunday. [read post]
10 Sep 2009, 9:59 pm
The case, Sanofi-Aventis U.S. [read post]
5 Oct 2017, 3:28 pm
Appellants Sanofi, Aventisub LLC, Regeneron PharmaceuticalsInc., and Sanofi-Aventis U.S., LLC (collectively,“Appellants”) appeal from a final judgment of thedistrict court holding U.S. [read post]
9 Jan 2024, 1:15 pm
Sanofi the Supreme Court spoke. [read post]
9 Jan 2024, 1:15 pm
Sanofi the Supreme Court spoke. [read post]
27 Aug 2019, 9:59 pm
The case arose in ANDA litigation involving Sanofi's Jevtana® (cabazitaxel), having the structure: where the methoxy... [read post]
21 Nov 2017, 4:15 am
Sanofi: A well characterized antigen insufficient for written description of an antibody appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
13 Dec 2010, 1:07 pm
Aiming to build support among Genzyme shareholders, Sanofi has extended its $69-per-share hostile bid--which was set to expire last week after being spurned by the Genzyme board--until January 21. [read post]
12 Jul 2011, 2:13 pm
One wonders whether Sanofi will continue to promote Multaq or, instead, move to withdraw it from the market. [read post]
1 Aug 2011, 8:41 am
Briefly, Sanofi-Aventis had an Australian patent on the compound, which expired in 2004. [read post]
26 Mar 2020, 5:56 pm
Sanofi-Aventis U.S. [read post]
27 Jul 2010, 4:55 am
Karst – As we thought might happen, Sanofi-aventis U.S. [read post]
30 Aug 2019, 12:45 pm
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha. [read post]
